3.22
price down icon6.67%   -0.23
after-market Dopo l'orario di chiusura: 3.22
loading
Precedente Chiudi:
$3.45
Aprire:
$3.3
Volume 24 ore:
2.01M
Relative Volume:
0.85
Capitalizzazione di mercato:
$576.06M
Reddito:
$25.55M
Utile/perdita netta:
$-341.97M
Rapporto P/E:
-1.15
EPS:
-2.8
Flusso di cassa netto:
$-304.44M
1 W Prestazione:
-4.17%
1M Prestazione:
+13.78%
6M Prestazione:
-31.63%
1 anno Prestazione:
-58.85%
Intervallo 1D:
Value
$3.194
$3.40
Intervallo di 1 settimana:
Value
$3.194
$3.64
Portata 52W:
Value
$1.775
$10.72

Relay Therapeutics Inc Stock (RLAY) Company Profile

Name
Nome
Relay Therapeutics Inc
Name
Telefono
617-370-8837
Name
Indirizzo
399 BINNEY STREET, CAMBRIDGE
Name
Dipendente
259
Name
Cinguettio
Name
Prossima data di guadagno
2025-02-21
Name
Ultimi documenti SEC
Name
RLAY's Discussions on Twitter

Confronta RLAY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RLAY
Relay Therapeutics Inc
3.22 576.06M 25.55M -341.97M -304.44M -2.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
455.45 115.69B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
529.24 53.25B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
307.99 39.22B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
577.89 35.78B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
269.63 27.68B 3.81B -644.79M -669.77M -6.24

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-17 Iniziato Wells Fargo Equal Weight
2024-09-10 Ripresa Goldman Buy
2024-09-10 Aggiornamento Jefferies Hold → Buy
2024-09-10 Downgrade Oppenheimer Outperform → Perform
2024-05-10 Aggiornamento Barclays Equal Weight → Overweight
2023-04-20 Aggiornamento Jefferies Underperform → Hold
2023-04-19 Aggiornamento Raymond James Outperform → Strong Buy
2023-04-13 Iniziato Raymond James Outperform
2023-02-03 Iniziato Oppenheimer Outperform
2022-09-30 Iniziato Barclays Equal Weight
2022-09-02 Iniziato Stifel Buy
2022-06-06 Iniziato Jefferies Underperform
2022-02-01 Iniziato Berenberg Buy
2021-07-21 Iniziato BofA Securities Buy
2020-12-15 Reiterato H.C. Wainwright Buy
2020-12-08 Iniziato JMP Securities Mkt Outperform
2020-11-05 Iniziato H.C. Wainwright Buy
2020-08-10 Iniziato Cowen Outperform
2020-08-10 Iniziato Goldman Buy
2020-08-10 Iniziato Guggenheim Buy
2020-08-10 Iniziato JP Morgan Neutral
Mostra tutto

Relay Therapeutics Inc Borsa (RLAY) Ultime notizie

pulisher
Jun 12, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by California State Teachers Retirement System - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors | RLAY Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 11, 2025

Relay Therapeutics Appoints Claire Mazumdar to Board of Directors - citybiz

Jun 11, 2025
pulisher
Jun 11, 2025

# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial - Investing.com India

Jun 11, 2025
pulisher
Jun 11, 2025

# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial By Investing.com - Investing.com South Africa

Jun 11, 2025
pulisher
Jun 11, 2025

Relay Therapeutics Appoints Claire Mazumdar To Board Of Directors - marketscreener.com

Jun 11, 2025
pulisher
Jun 11, 2025

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors - Bluefield Daily Telegraph

Jun 11, 2025
pulisher
Jun 11, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 9,293 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory - Insider Monkey

Jun 09, 2025
pulisher
Jun 06, 2025

Relay Therapeutics Holds 2025 Annual Stockholder Meeting - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Layoff Tracker: Capsida Downsizes as Part of Shift to Clinical-Stage Company - BioSpace

Jun 06, 2025
pulisher
Jun 05, 2025

Relay Therapeutics (RLAY) Gets a Hold from Wells Fargo - The Globe and Mail

Jun 05, 2025
pulisher
Jun 04, 2025

Relay Therapeutics Announces Lease Termination Agreement - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by Bank of America Corp DE - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Citizens JMP maintains Relay Therapeutics stock rating after trial data By Investing.com - Investing.com Canada

Jun 03, 2025
pulisher
Jun 03, 2025

Nuveen Asset Management LLC Increases Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Jane Street Group LLC Cuts Stock Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Relay Therapeutics reports promising breast cancer drug data By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

Relay Therapeutics’ RLY-2608 Shows Promising 11-Month PFS in Breast Cancer - Insider Monkey

Jun 02, 2025
pulisher
Jun 02, 2025

Relay Therapeutics, Inc. Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival At Asco 2025 - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Relay Therapeutics (RLAY) Shares Positive Interim Results for RL - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Relay Therapeutics reports promising breast cancer drug data - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 | RLAY Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 - TradingView

Jun 02, 2025
pulisher
Jun 02, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock Position Lifted by ProShare Advisors LLC - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Deutsche Bank AG Purchases 30,278 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

Jun 01, 2025
pulisher
Jun 01, 2025

Ameriprise Financial Inc. Purchases 28,989 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 17,009 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

May 31, 2025
pulisher
May 30, 2025

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June - The Manila Times

May 30, 2025
pulisher
May 29, 2025

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June | RLAY Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Relay Therapeutics Management to Share Latest Precision Medicine Strategy at Two Major Healthcare Conferences - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Relay Therapeutics to Participate in Two Upcoming Investor Confe - GuruFocus

May 29, 2025
pulisher
May 28, 2025

Relay Therapeutics’ SWOT analysis: ai-driven biotech stock faces pivotal year - Investing.com Nigeria

May 28, 2025
pulisher
May 27, 2025

Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders - Quantisnow

May 27, 2025
pulisher
May 27, 2025

Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders – Company Announcement - Financial Times

May 27, 2025
pulisher
May 26, 2025

Man Group plc Buys Shares of 173,605 Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

May 26, 2025
pulisher
May 24, 2025

What Makes Relay Therapeutics (RLAY) a New Buy Stock - MSN

May 24, 2025
pulisher
May 22, 2025

Northern Trust Corp Buys 231,713 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

May 22, 2025
pulisher
May 21, 2025

BNP Paribas Financial Markets Invests $987,000 in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

May 21, 2025
pulisher
May 17, 2025

Stifel Financial Corp Makes New Investment in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

May 17, 2025
pulisher
May 16, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World

May 16, 2025
pulisher
May 15, 2025

Transcript : Relay Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com

May 15, 2025
pulisher
May 13, 2025

Relay Therapeutics, Inc. (RLAY): One of the Best Low Priced Biotech Stocks to Buy Now - Yahoo Finance

May 13, 2025
pulisher
May 12, 2025

10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey

May 12, 2025
pulisher
May 12, 2025

HC Wainwright Issues Optimistic Forecast for RLAY Earnings - Defense World

May 12, 2025
pulisher
May 11, 2025

89,949 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Purchased by First Trust Advisors LP - Defense World

May 11, 2025
pulisher
May 10, 2025

Dimensional Fund Advisors LP Grows Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

May 10, 2025

Relay Therapeutics Inc Azioni (RLAY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Relay Therapeutics Inc Azioni (RLAY) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Rahmer Peter
See remarks
Apr 28 '25
Sale
3.17
1,364
4,324
400,820
Catinazzo Thomas
Chief Financial Officer
Apr 30 '25
Sale
3.00
12,943
38,829
355,376
Catinazzo Thomas
Chief Financial Officer
Apr 29 '25
Sale
3.23
3,558
11,492
368,319
Catinazzo Thomas
Chief Financial Officer
Apr 28 '25
Sale
3.17
2,690
8,527
371,877
Bergstrom Donald A
President, R&D
Apr 30 '25
Sale
3.00
27,472
82,416
583,490
Bergstrom Donald A
President, R&D
Apr 28 '25
Sale
3.17
4,090
12,965
610,962
Adams Brian
Chief Legal Officer
Apr 30 '25
Sale
3.00
12,943
38,829
391,385
Adams Brian
Chief Legal Officer
Apr 28 '25
Sale
3.17
1,644
5,211
404,328
$98.73
price up icon 1.91%
$22.82
price down icon 1.17%
$34.84
price down icon 1.22%
$19.78
price down icon 1.88%
$106.57
price up icon 1.57%
biotechnology ONC
$269.63
price down icon 2.50%
Capitalizzazione:     |  Volume (24 ore):